ss-31 peptide kidney SS-31 for CKD (Chronic Kidney Disease - SS-31 peptidereview SS-31 can reduce acute kidney injury The Protective Power of SS-31 Peptide in Kidney Health

SS-31 peptidebenefits The intricate functions of the kidney are vital for overall health, and maintaining their optimal performance is crucial. Emerging research highlights the potential of SS-31 peptide, a mitochondria-targeting antioxidant, in safeguarding kidney health, particularly in the context of various kidney diseases. This peptide has garnered significant attention for its ability to ameliorate kidney damage by targeting the core of cellular energy production and protection: mitochondria.

SS-31 peptide is a unique molecule that specifically targets the inner mitochondrial membraneSS-31 improves kidney mitochondrial functionafter IR injury. Rats were subcutaneously treated with saline or SS-31 (2 mg/kg) 30 minutes before occlusion of .... Its primary mechanism of action involves binding to cardiolipin, a crucial phospholipid found in the inner mitochondrial membrane. This binding action helps to stabilize mitochondrial structure and function, particularly under conditions of stress, injury, or disease. By doing so, SS-31 effectively reduces mitochondrial reactive oxygen species (ROS) production, a key driver of oxidative stress and cellular damage in numerous pathological conditions.

Ameliorating Kidney Injury and Disease Progression

The impact of SS-31 peptide on kidney health is particularly evident in conditions like diabetic nephropathy (DN). Studies have shown that SS-31 improves kidney function in DN by acting as an antioxidant. Research indicates that SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.2023年5月10日—SS-31 can reduce acute kidney injuryinduced by iodine contrast agent in diabetes by protecting mitochondrial function and inhibiting the ROS-NLRP3 signaling ... Furthermore, SS-31 has demonstrated the ability to protect against high glucose (HG)-induced renal injury through this antioxidant mechanism. This protective effect is associated with improved renal function, including a reduction in urinary albumin excretion, proteinuria, serum creatinine, and an improvement in creatinine clearanceSS-31 (Elamipretide): FDA-Approved Mitochondrial Peptide.

Beyond diabetes, SS-31 also shows promise in other forms of kidney injury. It has been observed to reduce acute kidney injury (AKI), including that induced by iodine contrast agents in diabetic individuals, by protecting mitochondrial function and inhibiting the ROS-NLRP3 signaling pathway.2023年5月10日—SS-31 can reduce acute kidney injuryinduced by iodine contrast agent in diabetes by protecting mitochondrial function and inhibiting the ROS-NLRP3 signaling ... This peptide’s ability to protect against ischemic kidney injury further underscores its broad nephroprotective capabilities.

Mechanisms of Action and Cellular Impact

The benefits of SS-31 peptide extend to various cellular components within the kidney. It has been shown to have protective benefits on glomerular mitochondria, leading to temporal changes in glomerular architecture.The mitochondrial-targeted peptide, SS-31, improves ... In the context of diabetic mice, SS31 protected renal tubulointerstitial injury through a decrease in mitochondrial fragmentation, achieved by suppressing the expression of key proteins involved in mitochondrial dynamics like Drp1.

Moreover, SS-31 can control oxidative tissue damage in kidney diseases. It works by downregulating CD36, a molecule implicated in kidney inflammation and fibrosis, and thereby improves renal function. A significant aspect of its action is its ability to prevent oxidative stress and mitochondrial dysfunction.2023年5月10日—SS-31 can reduce acute kidney injuryinduced by iodine contrast agent in diabetes by protecting mitochondrial function and inhibiting the ROS-NLRP3 signaling ... By stabilizing mitochondrial cardiolipin, SS-31 effectively attenuates cardiolipin loss in a dose-dependent manner, a critical factor that can lead to impaired mitochondrial respiration and increased ROS production.

Clinical Relevance and Future Prospects

The therapeutic potential of SS-31 peptide is being actively explored in clinical settings. It is currently under clinical trials for multiple mitochondrial disorders, including those impacting the kidney. This broad application highlights the fundamental role of mitochondrial health across various organ systems. SS-31 may also be promising in preventing atherosclerotic progression, which can have implications for renal artery health.

For individuals concerned about CKD (Chronic Kidney Disease) and diabetes, SS-31 for CKD and Diabetes is an area of significant research interest. The peptide's ability to target mitochondria and mitigate oxidative stress positions it as a potential therapeutic agent for managing these complex conditionsSS-31is believed to exert its effects by stabilizing the structure and function of mitochondria, particularly under conditions of stress or injury.. While specific SS-31 peptide dosage and SS-31 peptide protocol details are subjects of ongoing research and clinical trials, the overall findings suggest a robust therapeutic profile.

In conclusion, SS-31 peptide represents a significant advancement in the understanding and potential treatment of kidney diseases2019年6月2日—SS31 protected renal tubulointerstitial injury in diabetic micethrough a decrease in mitochondrial fragmentation via suppressing the expression of Drp1 and .... Its targeted action on mitochondria to combat oxidative stress and improve cellular function offers a promising avenue for protecting and restoring kidney health. As research continues, the role of this mitochondria-targeted antioxidant in clinical practice is expected to grow, offering hope for patients suffering from a range of kidney-related ailments.